A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease (PROPEL)
A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease Compared With Alglucosidase Alfa/Placebo
Sponsor: Amicus Therapeutics
Listed as NCT03729362, this PHASE3 trial focuses on Pompe Disease (Late-onset) and remains completed. Sponsored by Amicus Therapeutics, it has been updated 20 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
20 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 15 earlier versions
-
Apr 2022 — Oct 2023 [monthly]
Completed PHASE3
-
Nov 2021 — Apr 2022 [monthly]
Completed PHASE3
-
Mar 2021 — Nov 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2019 — Jan 2020 [monthly]
Recruiting PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Aug 2019 — Oct 2019 [monthly]
Recruiting PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
May 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amicus Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .